Takeda’s antibody-drug conjugate gets nod for China market
China has approved Japanese pharmaceutical giant Takeda’s cancer therapy Adcetris for treating patients with relapsed or refractory systemic anaplastic large cell lymphoma or Hodgkin lymphoma.
Chemically known as brentuximab, Adcetris is jointly developed by Takeda and Seattle Genetics. It is an antibody-drug conjugate that targets cancer cells expressing the CD30 receptor protein, currently approved for a number of indications across several markets including the U.S., Canada, the EU, and Japan.
The therapy was granted priority review status by the NMPA in June last year.
Chemically known as brentuximab, Adcetris is jointly developed by Takeda and Seattle Genetics. It is an antibody-drug conjugate that targets cancer cells expressing the CD30 receptor protein, currently approved for a number of indications across several markets including the U.S., Canada, the EU, and Japan.
The therapy was granted priority review status by the NMPA in June last year.
Covid-19 is fueling capital flow into China health care
Chinese health care and biotech companies have raised a record $6.8 billion this year amid heightened interest in the sector due to the global pandemic, Reuters reported.
“Because of the epidemic outbreak, the biotech, health care industry has been valued more by everyone. People realize that no matter what the economy looks like, patients always need to see the doctor,” said Xia Yu, co-founder and CEO of Akeso Biopharma.
Funds from IPOs have almost doubled to $2.1 billion compared to this time last year, according to Refinitiv data.
Health care experts are also expecting the government to invest more in the sector because the pandemic has highlighted its importance for the economy. In 2018, the country spent 6.6% of its GDP on health care, less than half of the 17.7% spent by the U.S.
“After the virus outbreak, government and society will greatly increase spending on health care systems, which will benefit the industry,” said Andy Lin, founding partner of Chinese private equity firm Loyal Valley Capital.
“Because of the epidemic outbreak, the biotech, health care industry has been valued more by everyone. People realize that no matter what the economy looks like, patients always need to see the doctor,” said Xia Yu, co-founder and CEO of Akeso Biopharma.
Funds from IPOs have almost doubled to $2.1 billion compared to this time last year, according to Refinitiv data.
Health care experts are also expecting the government to invest more in the sector because the pandemic has highlighted its importance for the economy. In 2018, the country spent 6.6% of its GDP on health care, less than half of the 17.7% spent by the U.S.
“After the virus outbreak, government and society will greatly increase spending on health care systems, which will benefit the industry,” said Andy Lin, founding partner of Chinese private equity firm Loyal Valley Capital.
More reads:
|
.png)
No hay comentarios:
Publicar un comentario